CBMX : Summary for CombiMatrix Corporation - Yahoo Finance

U.S. Markets open in 2 hrs 52 mins

CombiMatrix Corporation (CBMX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.45-0.15 (-4.17%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close3.60
Bid3.00 x 100
Ask3.95 x 100
Day's Range3.40 - 3.77
52 Week Range2.15 - 8.10
Avg. Volume280,756
Market Cap8.63M
PE Ratio (TTM)-0.67
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    CombiMatrix’s Pre-Implantation Genetic Screening by Next Generation Sequencing Granted Conditional Approval from New York State Department of Health

    IRVINE, Calif., Nov. 29, 2016-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that its pre-implantation ...

  • Zacks Small Cap Research2 months ago

    CBMX: Q3 Sets Across-The-Board Records. CF Break-Even Looks Attainable

    Déjà vu, except even better.  CombiMatrix (CBMX) reported financial results for the third quarter ending September 30th.  Not only was this the sixth straight quarter of improving profitability but sequential operating loss fell by an impressive 31%, from $1.2M in Q2 2016 to just $846k in Q3, marking the first time that operating loss fell below the $1M mark. Management has done a noteworthy job of growing the top line through a combination of test volume growth, expansion of the customer base (to a current record of 257), improved cash collections and higher average test pricing (or reimbursement).  But, in our opinion, what is even more impressive is that they’ve done so while also shedding expenses and improving margins.  The result has been revenue growing 26% yoy through the first nine months of 2016 (including 29% in Q3) and average gross margin and operating loss improving from 45.6% and $4.9M to 53.6% and $3.5M over the same period.

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
    Capital Cube2 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016

    Categories: Yahoo Finance Get free summary analysis CombiMatrix Corp. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings and NeoGenomics, Inc. (DGX-US, LH-US and NEO-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)